Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 7, 2009, Pages 2053-2058

  Heidebrecht Jr , Richard W ^a   Chenard, Melissa ^a   Close, Joshua ^a   Dahlberg, William K ^a   Fleming, Judith ^a   Grimm, Jonathan B ^a   Hamill, Julie E ^a   Harsch, Andreas ^a   Haines, Brian B ^a   Hughes, Bethany ^a   Kral, Astrid M ^a   Middleton, Richard E ^a   Mushti, Chandrasekhar ^a   Ozerova, Nicole ^a   Szewczak, Alexander A ^a   Wang, Hongmei ^a   Wilson, Kevin ^a   Witter, David J ^a   Secrist, J Paul ^a   Miller, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Pharmacokinetics; Phosphorus containing therapeutic; Selective histone deacetylase inhibitor; Xenograft; Zolinza

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PHOSPHINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOG; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HISTONE DEACETYLASES; MICE; MICE, NUDE; PHOSPHONIC ACIDS; REPRESSOR PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 61849130717     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.009     Document Type: Article

References (30)

1. Feinberg A.P., and Vogelstein B. Nature 301 (1983) 89
2. Holliday R. Science 238 (1987) 163
3. Jones P.A., and Baylin S.B. Nat. Rev. Genet. 3 (2002) 415
4. Grozinger C.M., and Schreiber S.L. Chem. Biol. 9 (2002) 3
5. Richon V.M. Br. J. Cancer 95 (2006) S2
6. O'Connor O.A. Br. J. Cancer 95 (2006) S7
7. Duvic M., and Zhang C. Br. J. Cancer 95 (2006) S13
8. Marks P.A., and Breslow R. Nat. Biotechnol. 25 (2007) 84
9. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. J. Med. Chem. 42 (1999) 3001
10. Kell J. Curr. Opin. Invest. Drugs 8 (2007) 485
11. Siliphaivahn P., Harrington P., Witter D.J., Otte K., Tempest P., Katter S., Kral A., Fleming J.C., Deshmukh S.V., Harsch A., Secrist P.J., and Miller T.A. Bioog. Med. Chem. Lett. 17 (2007) 4619
12. Moradei O.M., Mallais T.C., Frechette S., Paquin I., Tessier P.E., Leit S.M., Fournel M., Bonfils C., Trachy-Bourget M.-C., Liu J., Yan T.P., Lu A.-H., Rahil J., Wang J., Lefebvre S., Li Z., Vaisburg A.F., and Besterman J.M. J. Med. Chem. 50 (2007) 5543
13. Weerasinghe S.V.W., Estiu G., Wiest O., and Pflum M.K. J. Med. Chem. 51 (2008) 5542
14. Witter D.J., Harrington P., Wilson K.J., Chenard M., Cruz J.C., Fleming J.C., Harsch A., Kral A.M., Secrist J.P., and Miller T.A. Bioorg. Med. Chem. Lett. 18 (2008) 726
15. Methot J.L., Chenard M.C., Close J., Cruz J.C., Dahlberg W.K., Fleming J., Hamblett C.L., Hamill J.E., Harrington O., Harsch A., Heidebrecht R., Hughes B., Jung J., Kenific C.M., Kral A., Middleton R.E., Ozerova N., Sloman D.L., Stanton M.G., Szewcrak A., Witter D.J., Secrist J.P., and Miller T.A. Bioorg. Med. Chem. Lett. 18 (2008) 973
16. For the x-ray crystal structure of HDAC8. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188 RCSB Protein Data Bank number 1C3S
17. Gao Y., Luo J., Yao Z.-J., Guo R., Zou H., Kelley J., Voigt J., Yang D., and Burke R.R. J. Med. Chem. 43 (2000) 911
18. Markl G., Gschwender K., Rotzer I., and Kreitmeier P. Helv. Chim. Acta. 87 (2004) 825
19. Diethyl(4-carboxylphenyl)phosphonate, CAS 1527-34-0, ABCR, catalog number AB147504.
20. Denney D.B., Denney D.Z., Hammond P.J., and Wang Y.-P. J. Am. Chem. Soc. 103 (1981) 1785
21. Bhattacharya A.K., and Thyagarajan G. Chem. Rev. 81 (1981) 415
22. Methoxy-substituted examples saponified with superior results than the corresponding ethoxy examples, putatively as a result of the mechanism of alkaline hydrolysis. For a discussion of alkaline mechanism, see. Cook R.D., Diebert C.E., Schwarz W., Turley P.C., and Haake P. J. Am. Chem. Soc. 95 (1973) 8088
23. Acidic hydrolysis is more facile, but incompatible with our BOC protecting group. For a discussion of acidic mechanism, see. Abbas K., and Cook R.D. Tetrahedron Lett. 41 (1975) 3559
24. 1H-Benzotriazol-1-yl-oxytris(dimethylamino) phosphonium hexofluorophoshate (BOP), CAS 056602-33-6. It is worth noting that the dehydration reaction yields inferior results with diimides such as EDC.
25. Commercially available from Acros Organics, CAS 117196-73-3. For a preparation, see. Steere J.A., Sampson P.B., and Honek J.F. Bioorg. Med. Chem. Lett. 12 (2002) 457
26. For assay details, see Ref. 7b.
27. 50 = 0.460 μM) substituents.
28. Statistical significance was demonstrated via t-test analysis looking for a P-value of <0.05 relative to vehicle.
29. For assay details, see reference within. Jones P., Altamura S., Chakravarty P.K., Cecchetti O., De Francesco R., Gallinari P., Ingenito R., Meinke P.T., Petrocchi A., Rowley M., Scarpelli R., Serafini S., and Steinkühler C. Bioorg. Med. Chem. Lett. 16 (2006) 5948
30. The compounds described in this paper are the topic of a patent application. The reader is directed to this publication for experimental information: Close, J.; Grimm, J.; Heidebrecht, R. W.; Kattar, S.; Miller, T. A.; Otte, K. M.; Peterson, S.; Siliphaivanh, P.; Tempest, P.; Wilson, K. J.; Witter, D. J.; WO 2008010985.